Publication
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerPancreatic Carcinomacivic_curation1.00
- drugAkt Inhibitor MK2206civic_curation1.00
- geneKRAScivic_curation1.00
- genePTENcivic_curation1.00
- variantKRAS G12Dcivic_curation1.00
- variantPTEN Losscivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22025163
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KRAS G12D1 | ||||||||
| Akt Inhibitor MK2206 | Pancreatic Carcinoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID937Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss and a KRAS G12D mutation experienced a decrease of approximatel… (full text at CIViC) PMID 22025163 · Yap et al., 2011 · Open in CIViC | civic |
| PTEN Loss1 | ||||||||
| Akt Inhibitor MK2206 | Pancreatic Carcinoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID938Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss/KRAS G12D mutation experienced a decrease of approximately 60% … (full text at CIViC) PMID 22025163 · Yap et al., 2011 · Open in CIViC | civic |